DNAnexus IPO
DNAnexus provides a cloud-based platform for genomic data analysis and management, serving pharmaceutical companies, research institutions, and healthcare organizations. The company offers secure, scalable infrastructure for processing large-scale genomic datasets and running bioinformatics workflows. Investors are interested in its position within the growing precision medicine and genomics market.
Key Facts
| Industry | Biotechnology |
| Founded | 2009 |
| Headquarters | Mountain View, CA |
| Employees | 500-1,000 |
| Website | dnanexus.com |
| Funding | Series C funding. Total raised: ~$200M |
About DNAnexus
DNAnexus operates a cloud-based platform for genomic data analysis and management, serving pharmaceutical companies, biotechnology firms, and research institutions. The platform provides secure, scalable infrastructure for storing, analyzing, and sharing large-scale genomic datasets, enabling drug discovery, clinical trial support, and precision medicine initiatives.
The company has established itself as a critical infrastructure provider in the genomics space, processing petabytes of genomic data and supporting major biobanks and population health studies. DNAnexus differentiates itself through its regulatory compliance capabilities, including support for FDA submissions and clinical-grade data analysis, making it particularly valuable for pharmaceutical companies conducting genomics-driven drug development programs.
IPO Status
DNAnexus has not announced IPO plans and continues to operate as a private company serving the genomics and pharmaceutical research markets. The company has raised multiple rounds of venture funding over the years and has established partnerships with major pharmaceutical companies and research institutions. The genomics market has significant long-term potential, but companies typically need substantial recurring revenue and clear market leadership before going public. As a B2B platform serving specialized markets, DNAnexus would likely need to demonstrate strong customer retention, expanding use cases, and a path to profitability before considering an IPO. The regulatory environment around genomic data and healthcare applications also influences timing considerations for companies in this space.
Competitors
Frequently Asked Questions
Does DNAnexus have a stock?
No, DNAnexus has not had an IPO and remains a private company. The genomics platform provider has not made any announcements about going public.
When is the DNAnexus IPO date?
DNAnexus has not announced an IPO date or timeline. The company continues to focus on growing its genomics platform and serving pharmaceutical and research clients.
How can I buy DNAnexus stock?
DNAnexus stock is not publicly available as the company is private. If they eventually pursue an IPO, shares would become available through public exchanges.
Stay Updated on the DNAnexus IPO
Get real-time alerts when DNAnexus files for an IPO, prices shares, or begins trading.
Get IPO Alerts